
  
    
      
        Background_NNP
        Quality_NNP of_IN life_NN can_MD be_VB improved_VBN by_IN enhancing_VBG standards_NNS
        of_IN medical_JJ treatment_NN at_IN all_DT levels_NNS of_IN the_DT health_NN care_NN
        delivery_NN system_NN ._. Setting_VBG standards_NNS and_CC assessing_VBG the_DT
        quality_NN of_IN care_NN through_IN performance_NN review_NN should_MD become_VB
        part_NN of_IN everyday_JJ clinical_JJ practice_NN [_NN 1_CD ]_NN ._. The_DT study_NN of_IN
        prescribing_VBG patterns_NNS seeks_VBZ to_TO monitor_VB ,_, evaluate_VB and_CC suggest_VBP
        modifications_NNS in_IN practitioners_NNS '_POS prescribing_VBG habits_NNS so_RB as_IN to_TO
        make_VB medical_JJ care_NN rational_JJ and_CC cost_VB effective_JJ ._.
        Information_NNP about_IN antibiotic_JJ use_NN patterns_NNS is_VBZ necessary_JJ
        for_IN a_DT constructive_JJ approach_NN to_TO problems_NNS that_WDT arise_VBP from_IN the_DT
        multiple_JJ antibiotics_NNS available_JJ [_NN 2_CD ]_NN ._. In_IN developing_VBG
        countries_NNS the_DT cost_NN of_IN health_NN care_NN is_VBZ a_DT matter_NN of_IN major_JJ
        concern_NN [_NN 3_CD ]_NN ._. This_DT is_VBZ especially_RB true_JJ for_IN Nepal_NNP ,_, a_DT
        developing_VBG country_NN in_IN South_NNP Asia_NNP ._. Excessive_NNP and_CC
        inappropriate_JJ use_NN of_IN antibiotics_NNS in_IN hospitals_NNS ,_, health_NN care_NN
        facilities_NNS and_CC the_DT community_NN contributes_VBZ to_TO the_DT development_NN
        of_IN bacterial_JJ resistance_NN ._. In_IN India_NNP reports_NNS on_IN antibiotic_JJ
        utilization_NN at_IN an_DT institutional_JJ level_NN include_VBP both_DT
        cross-sectional_JJ [_NN 3_CD ]_NN and_CC longitudinal_NN studies_NNS [_NN 4_CD 5_CD ]_NN of_IN
        prescribing_VBG patterns_NNS ._.
        The_DT ATC_NNP (_( anatomic-therapeutic-chemical_JJ )_) classification_NN
        assigns_VBZ code_NN letters_NNS and_CC numbers_NNS to_TO drugs_NNS [_NN 6_CD 7_CD ]_NN ._. The_DT
        defined_VBN daily_JJ dose_NN (_( DDD_NNP )_) concept_NN was_VBD developed_VBN to_TO overcome_VB
        objections_NNS against_IN traditional_JJ units_NNS of_IN drug_NN consumption_NN [_NN
        6_CD ]_NN ._. The_DT DDD_NNP for_IN a_DT given_VBN drug_NN is_VBZ established_VBN on_IN the_DT basis_NN
        of_IN an_DT assumed_VBN average_JJ use_NN per_IN day_NN of_IN the_DT drug_NN for_IN its_PRP$ main_JJ
        indication_NN in_IN adults_NNS [_NN 6_CD ]_NN ._. DDD_NNP will_MD be_VB assigned_VBN only_RB for_IN
        drugs_NNS that_WDT already_RB have_VBP an_DT ATC_NNP code_NN ._. DDD_NNP is_VBZ a_DT unit_NN of_IN
        measurement_NN and_CC may_MD not_RB reflect_VB the_DT prescribed_VBN daily_JJ dose_NN ,_,
        however_RB they_PRP provide_VBP a_DT fixed_VBN unit_NN of_IN measurement_NN
        independent_JJ of_IN price_NN and_CC formulation_NN and_CC enable_VB the_DT
        researcher_NN to_TO perform_VB comparisons_NNS between_IN population_NN
        groups_NNS ._. DDD_NNP /_NN 100_CD bed-days_JJ provides_VBZ a_DT rough_JJ estimate_NN of_IN
        consumption_NN of_IN drugs_NNS among_IN hospital_NN in-patients_JJ ._.
        Information_NNP on_IN antibiotic_JJ use_NN patterns_NNS ,_, the_DT illnesses_NNS
        for_IN which_WDT antibiotics_NNS are_VBP prescribed_VBN and_CC the_DT DDD_NNP /_NN 100_CD
        bed-days_JJ of_IN commonly_RB used_VBN antibiotics_NNS in_IN hospitals_NNS in_IN
        Western_NNP Nepal_NNP are_VBP lacking_VBG ._. Hence_RB the_DT present_JJ study_NN was_VBD
        carried_VBN out_IN over_IN 3_CD months_NNS (_( 01_CD ._. 04_CD ._. 02_CD to_TO 30_CD ._. 06_CD ._. 02_CD )_) at_IN the_DT
        Manipal_NNP Teaching_NNP Hospital_NNP ,_, a_DT tertiary_JJ care_NN hospital_NN
        attached_VBN to_TO the_DT Manipal_NNP College_NNP of_IN Medical_NNP Sciences_NNPS ,_,
        Pokhara_NNP ,_, Nepal_NNP ._.
        The_DT objectives_NNS of_IN the_DT study_NN were_VBD to_TO :_:
        1_LS )_) collect_VB relevant_JJ demographic_JJ information_NN and_CC
        information_NN on_IN duration_NN of_IN hospitalization_NN of_IN patients_NNS
        admitted_VBN to_TO the_DT Internal_NNP Medicine_NNP ward_VB and_CC prescribed_VBN
        antibiotics_NNS during_IN the_DT study_NN ._.
        2_LS )_) obtain_VB information_NN on_IN the_DT antibiotic_JJ prescribing_VBG
        pattern_NN and_CC the_DT disease_NN conditions_NNS for_IN which_WDT antibiotics_NNS
        were_VBD prescribed_VBN ._.
        3_LS )_) obtain_VB information_NN on_IN the_DT common_JJ organisms_NNS isolated_VBN
        during_IN culture_NN and_CC sensitivity_NN testing_NN and_CC their_PRP$ antibiotic_JJ
        sensitivity_NN patterns_NNS ._.
        4_LS )_) apply_VB the_DT ATC_NNP classification_NN to_TO the_DT commonly_RB used_VBN
        antibiotics_NNS and_CC to_TO calculate_VB their_PRP$ DDDs_NNP /_NN 100_CD bed-days_JJ ._.
        5_LS )_) calculate_VB the_DT mean_NN Â±_NN SD_NNP cost_NN of_IN antibiotics_NNS per_IN
        prescription_NN ._.
      
      
        Methods_NNP
        The_DT study_NN was_VBD carried_VBN out_IN over_IN a_DT three-month_JJ period_NN at_IN
        the_DT Manipal_NNP Teaching_NNP Hospital_NNP ,_, Pokhara_NNP ,_, Nepal_NNP ._. Patients_NNS
        admitted_VBD to_TO the_DT Internal_NNP Medicine_NNP ward_VB who_WP were_VBD prescribed_VBN
        antibiotics_NNS were_VBD included_VBN in_IN the_DT study_NN and_CC were_VBD identified_VBN
        manually_RB ._. This_DT may_MD have_VB the_DT potential_NN for_IN bias_NN and_CC errors_NNS ._.
        Quantitative_NNP estimation_NN of_IN the_DT bias_NN has_VBZ not_RB been_VBN carried_VBN
        out_IN in_IN this_DT study_NN ._. Computerization_NNP of_IN the_DT Medical_NNP Records_NNPS
        Department_NNP is_VBZ in_IN progress_NN and_CC there_EX is_VBZ a_DT proposal_NN for_IN
        storing_VBG the_DT hospital_NN records_NNS in_IN a_DT computerized_JJ format_NN ._. This_DT
        may_MD help_VB in_IN reducing_VBG any_DT potential_JJ bias_NN ._.
        The_DT age_NN and_CC sex_NN of_IN the_DT patients_NNS ,_, clinical_JJ diagnosis_NN ,_,
        duration_NN of_IN hospitalization_NN ,_, antibiotic_JJ information_NN (_( name_NN ,_,
        dose_NN and_CC frequency_NN )_) and_CC the_DT results_NNS of_IN culture_NN and_CC
        sensitivity_NN testing_NN were_VBD entered_VBN into_IN the_DT patient_NN indicator_NN
        form_NN (_( PIF_NNP )_) [_NN see_VB Additional_JJ file_NN 1_CD ]_NN ._. The_DT antibiotics_NNS
        prescribed_VBN for_IN parenteral_NN use_NN and_CC indications_NNS for_IN their_PRP$ use_NN
        were_VBD also_RB analyzed_VBN separately_RB ._. Antibiotics_NNP were_VBD used_VBN for_IN :_:
        prophylaxis_NNS ,_, bacteriologically_RB proven_VBN infection_NN (_( BPI_NNP )_) or_CC
        non-bacteriologically_JJ proven_VBN infection_NN (_( non-_NN BPI_NNP )_) ._. Details_NNS
        of_IN antibiotic_JJ use_NN in_IN BPI_NNP were_VBD noted_VBN ._.
        Additional_JJ File_NNP 1_CD
        Patient_NNP indicator_NN form_NN ._. Description_NNP of_IN data_NNS :_: Format_NNP used_VBD
        to_TO enter_VB information_NN about_IN the_DT patients_NNS
        Click_NNP here_RB for_IN file_NN
        The_DT mean_JJ cost_NN of_IN antibiotics_NNS prescribed_VBN during_IN the_DT
        hospital_NN stay_NN and_CC on_IN discharge_NN from_IN the_DT hospital_NN was_VBD noted_VBN ._.
        The_DT cost_NN of_IN antibiotics_NNS prescribed_VBN during_IN the_DT hospital_NN stay_NN
        was_VBD determined_VBN using_VBG the_DT price_NN list_NN supplied_VBN by_IN the_DT
        hospital_NN pharmacy_NN ._.
        Patients_NNS with_IN a_DT monthly_JJ family_NN income_NN less_JJR than_IN 2000_CD
        Nepalese_NNP rupees_NNS (_( 1_CD US_NNP $_$ =_SYM 78_CD Nepalese_NNP rupees_NNS )_) were_VBD taken_VBN as_IN
        belonging_VBG to_TO low_JJ socioeconomic_JJ status_NN ;_: those_DT with_IN a_DT monthly_JJ
        income_NN between_IN 2000_CD to_TO 4000_CD rupees_NNS and_CC more_JJR than_IN 4000_CD
        rupees_NNS were_VBD taken_VBN as_IN belonging_VBG to_TO middle_JJ and_CC high_JJ
        socioeconomic_JJ status_NN respectively_RB ._. The_DT socioeconomic_JJ
        classification_NN was_VBD worked_VBN out_IN by_IN Mr_NNP ._. Theodore_NNP of_IN the_DT
        Community_NNP Medicine_NNP department_NN of_IN our_PRP$ institution_NN with_IN input_NN
        from_IN the_DT Statistics_NNP department_NN of_IN the_DT Green_NNP Pasture_NNP
        hospital_NN ,_, Pokhara_NNP ._. The_DT average_NN per_IN capita_NN income_NN of_IN Nepal_NNP
        was_VBD the_DT major_JJ consideration_NN while_IN preparing_VBG the_DT
        classification_NN which_WDT had_VBD been_VBN previously_RB tested_VBN during_IN the_DT
        field_NN visits_NNS by_IN the_DT Community_NNP Medicine_NNP department_NN ._. Housing_NNP ,_,
        the_DT extent_NN of_IN land_NN holdings_NNS ,_, and_CC material_NN possessions_NNS owned_VBN
        by_IN the_DT respondents_NNS were_VBD examined_VBN in_IN these_DT field_NN visits_NNS ._.
        Respondents_NNP were_VBD also_RB asked_VBN about_IN their_PRP$ family_NN income_NN when_WRB
        interviewed_VBN in_IN the_DT ward_NN ,_, (_( the_DT limitation_NN being_VBG that_IN we_PRP were_VBD
        entirely_RB dependent_JJ on_IN the_DT respondents_NNS answer_VBP and_CC had_VBD no_DT
        means_VBZ to_TO cross_VB check_NN the_DT same_JJ ,_, as_IN in_IN the_DT field_NN visits_NNS ._. )_)
        The_DT percentage_NN of_IN antibiotics_NNS prescribed_VBN from_IN the_DT
        Essential_NNP drug_NN list_NN of_IN Nepal_NNP [_NN 8_CD ]_NN and_CC from_IN the_DT WHO_WP list_NN of_IN
        Essential_NNP drugs_NNS [_NN 9_CD ]_NN and_CC the_DT DDD_NNP /_NN 100_CD bed-days_JJ of_IN the_DT 10_CD
        most_RBS commonly_RB prescribed_VBN antibiotics_NNS in_IN the_DT Internal_NNP
        Medicine_NNP ward_VB ,_, was_VBD calculated_VBN ._. The_DT DDD_NNP /_NN 100_CD bed-days_JJ of_IN the_DT
        individual_JJ antibiotics_NNS were_VBD added_VBN together_RB to_TO get_VB the_DT total_JJ
        antibiotic_JJ consumption_NN ._. Ciprofloxacin_NNP has_VBZ two_CD DDDs_NNP ,_, one_CD for_IN
        oral_JJ use_NN of_IN the_DT antibiotic_JJ and_CC the_DT other_JJ for_IN parenteral_NN
        use_NN ._. The_DT 2_CD DDDs_NNP /_NN 100_CD bed-days_JJ were_VBD calculated_VBN separately_RB and_CC
        then_RB were_VBD added_VBN to_TO measure_VB the_DT total_JJ consumption_NN of_IN
        ciprofloxacin_NN in_IN DDDs_NNP /_NN 100_CD bed-days_JJ ._. DDD_NNP /_NN 100_CD bed-days_JJ was_VBD
        calculated_VBN by_IN the_DT formula_NN :_:
        
        The_DT institutional_JJ review_NN board_NN of_IN the_DT Manipal_NNP College_NNP of_IN
        Medical_NNP Sciences_NNPS ,_, Pokhara_NNP ,_, Nepal_NNP ,_, approved_VBD the_DT study_NN ._.
      
      
        Results_NNS
        Two_CD hundred_CD and_CC three_CD of_IN the_DT 687_CD patients_NNS admitted_VBN to_TO
        the_DT Internal_NNP Medicine_NNP ward_VB were_VBD prescribed_VBN antibiotics_NNS
        during_IN the_DT study_NN period_NN ._. Out_IN of_IN the_DT total_NN of_IN 203_CD patients_NNS ,_,
        112_CD (_( 55_CD ._. 2_LS %_NN )_) were_VBD male_JJ ._. One_CD hundred_CD and_CC four_CD patients_NNS
        (_( 51_CD ._. 2_LS %_NN )_) were_VBD above_IN the_DT age_NN of_IN 59_CD years_NNS ._. Regarding_VBG the_DT
        ethnic_JJ composition_NN ,_, 56_CD patients_NNS (_( 27_CD ._. 6_CD %_NN )_) were_VBD Gurungs_NNP while_IN
        50_CD patients_NNS (_( 24_CD ._. 6_CD %_NN )_) were_VBD Brahmins_NNP ._. The_DT other_JJ common_JJ
        ethnic_JJ /_NN caste_NN groups_NNS in_IN the_DT study_NN were_VBD Chettris_NNP [_NN 43_CD patients_NNS
        (_( 21_CD ._. 2_LS %_NN )_) ]_NN ,_, Bishwakarmas_NNP [_NN 15_CD patients_NNS (_( 7_CD ._. 4_LS %_NN )_) ]_NN and_CC Newars_NNP [_NN 11_CD
        patients_NNS (_( 5_CD ._. 4_LS %_NN )_) ]_NN ._. One_CD hundred_CD and_CC eighteen_NN patients_NNS (_( 58_CD ._. 1_LS %_NN )_)
        belonged_VBD to_TO an_DT urban_JJ area_NN while_IN the_DT remaining_VBG were_VBD from_IN
        rural_JJ areas_NNS ._.
        Figure_NN 1_CD shows_VBZ the_DT number_NN of_IN antibiotics_NNS prescribed_VBN
        during_IN the_DT period_NN of_IN hospital_NN stay_NN ._. Ninety-eight_NNP patients_NNS
        were_VBD prescribed_VBN a_DT single_JJ antibiotic_NN ,_, while_IN 75_CD patients_NNS were_VBD
        prescribed_VBN two_CD antibiotics_NNS ._. Twenty-three_NNP patients_NNS were_VBD
        prescribed_VBN 3_CD antibiotics_NNS ,_, while_IN 4_CD and_CC 5_CD antibiotics_NNS were_VBD
        prescribed_VBN to_TO 5_CD and_CC 2_CD patients_NNS respectively_RB ._.
        The_DT duration_NN of_IN hospitalization_NN of_IN the_DT 203_CD patients_NNS was_VBD
        recorded_VBN ._. One_CD hundred_CD and_CC one_CD patients_NNS (_( 49_CD ._. 7_CD %_NN )_) were_VBD
        hospitalized_VBN for_IN a_DT time_NN period_NN ranging_VBG from_IN 4_CD to_TO 7_CD days_NNS ._.
        Median_JJ duration_NN of_IN hospitalization_NN was_VBD 5_CD days_NNS and_CC the_DT
        interquartile_NN range_NN was_VBD 3_CD days_NNS ._. The_DT corresponding_JJ figures_NNS
        for_IN hospitalized_VBN patients_NNS who_WP were_VBD not_RB prescribed_VBN an_DT
        antibiotic_NN were_VBD 3_CD and_CC 2_CD days_NNS respectively_RB ._.
        The_DT most_RBS common_JJ condition_NN for_IN which_WDT an_DT antibiotic_NN was_VBD
        prescribed_VBN was_VBD chronic_JJ obstructive_JJ pulmonary_JJ disease_NN (_( COPD_NNP )_)
        (_( 22_CD ._. 7_CD %_NN )_) ._. The_DT other_JJ common_JJ conditions_NNS were_VBD lower_JJR respiratory_JJ
        tract_NN infections_NNS (_( LRTI_NNP )_) (_( 15_CD ._. 8_CD %_NN )_) ,_, urinary_JJ tract_NN infections_NNS
        (_( UTI_NNP )_) (_( 13_CD ._. 3_LS %_NN )_) and_CC pneumonia_NN (_( 8_CD ._. 9_CD %_NN )_) ._. One_CD hundred_CD and_CC seventy_NN
        three_CD patients_NNS were_VBD discharged_VBN ,_, 7_CD patients_NNS died_VBD ,_, 8_CD patients_NNS
        were_VBD discharged_VBN at_IN request_NN and_CC 5_CD were_VBD transferred_VBN to_TO the_DT
        Intensive_NNP Care_NNP Unit_NNP (_( ICU_NNP )_) ._. Six_CD patients_NNS left_VBN against_IN
        medical_JJ advice_NN while_IN 4_CD patients_NNS were_VBD referred_VBN to_TO other_JJ
        hospitals_NNS ._.
        Sixty-eight_NNP patients_NNS (_( 33_CD ._. 5_LS %_NN )_) belonged_VBD to_TO the_DT lower_JJR
        socioeconomic_JJ group_NN while_IN 112_CD patients_NNS (_( 55_CD ._. 2_LS %_NN )_) and_CC 23_CD
        patients_NNS (_( 11_CD ._. 3_LS %_NN )_) were_VBD from_IN the_DT middle_JJ and_CC high_JJ
        socioeconomic_JJ groups_NNS respectively_RB ._. Three_CD hundred_CD and_CC forty_NN
        seven_CD patient_NN antibiotics_NNS were_VBD prescribed_VBN ._. Table_NNP 1_CD shows_VBZ the_DT
        frequency_NN of_IN prescribing_VBG of_IN the_DT 5_CD most_RBS commonly_RB prescribed_VBN
        antibiotics_NNS ._. One_CD hundred_CD and_CC seventy_NN six_CD patient_NN
        antibiotics_NNS (_( 51_CD %_NN )_) were_VBD prescribed_VBN parenterally_RB ._.
        Antibiotics_NNP were_VBD used_VBN for_IN BPI_NNP in_IN 65_CD patients_NNS ,_, non-_NN BPI_NNP in_IN
        126_CD patients_NNS and_CC for_IN prophylaxis_NNS in_IN 12_CD patients_NNS ._. Mean_VB Â±_NN SD_NNP
        cost_NN of_IN antibiotics_NNS prescribed_VBN during_IN the_DT hospital_NN stay_NN was_VBD
        1236_CD Â±_NN 1002_CD Nepalese_NNP rupees_NNS (_( 16_CD ._. 5_LS Â±_NN 13_CD ._. 4_LS US_NNP $_$ )_) ._. Parenteral_NNP
        antibiotics_NNS accounted_VBD for_IN 80_CD ._. 3_LS %_NN of_IN the_DT total_JJ cost_NN ._.
        Antibiotics_NNP were_VBD prescribed_VBN at_IN the_DT time_NN of_IN discharge_NN in_IN 145_CD
        patients_NNS with_IN amoxicillin_NN (_( 55_CD patients_NNS )_) being_VBG most_RBS commonly_RB
        prescribed_VBN ._. The_DT other_JJ commonly_RB prescribed_VBN antibiotics_NNS on_IN
        discharge_NN were_VBD ciprofloxacin_NN (_( 18_CD patients_NNS )_) ,_, ampicillin_NN (_( 11_CD
        patients_NNS )_) and_CC metronidazole_NN (_( 10_CD patients_NNS )_) ._.
        Of_IN the_DT 347_CD patient_NN antibiotics_NNS prescribed_VBN ,_, 233_CD (_( 67_CD ._. 1_LS %_NN )_)
        were_VBD prescribed_VBN from_IN the_DT Essential_NNP drug_NN list_NN of_IN Nepal_NNP [_NN 8_CD ]_NN
        and_CC 226_CD (_( 65_CD ._. 1_LS %_NN )_) from_IN WHO_WP Essential_NNP drug_NN list_NN [_NN 9_CD ]_NN ._. One_CD
        hundred_CD and_CC twelve_CD patient_NN antibiotics_NNS (_( 32_CD ._. 3_LS %_NN )_) were_VBD used_VBN in_IN
        BPI_NNP ._. Ampicillin_NNP (_( 24_CD ._. 8_CD %_NN )_) ,_, amoxicillin_NN (_( 16_CD ._. 7_CD %_NN )_) ,_, metronidazole_NN
        (_( 13_CD ._. 3_LS %_NN )_) ciprofloxacin_NN (_( 11_CD ._. 5_LS %_NN )_) and_CC crystalline_JJ penicillin_NN
        (_( 8_CD ._. 1_LS %_NN )_) were_VBD the_DT predominant_NN antibiotics_NNS ._. Other_JJ antibiotics_NNS
        (_( 25_CD ._. 6_CD %_NN )_) included_VBD norfloxacin_NN ,_, cephalexin_NN ,_, cotrimoxazole_NN and_CC
        cefotaxime_NN ._. Sixty-three_NNP (_( 56_CD ._. 2_LS %_NN )_) of_IN the_DT 112_CD patient_NN
        antibiotics_NNS used_VBN in_IN BPI_NNP were_VBD prescribed_VBN by_IN the_DT parenteral_NN
        route_NN ._.
        Table_NNP 2_CD shows_VBZ the_DT ATC_NNP codes_NNS and_CC the_DT DDDs_NNP /_NN 100_CD bed_NN days_NNS of_IN
        the_DT 10_CD most_RBS commonly_RB used_VBN antibiotics_NNS in_IN the_DT Internal_NNP
        Medicine_NNP ward_VB ._. The_DT study_NN was_VBD carried_VBN out_IN for_IN a_DT period_NN of_IN 90_CD
        days_NNS ,_, the_DT number_NN of_IN beds_NNS in_IN the_DT Internal_NNP Medicine_NNP ward_VB was_VBD
        60_CD and_CC the_DT average_JJ occupancy_NN index_NN during_IN the_DT study_NN period_NN
        was_VBD 0_CD ._. 7_CD ._.
        Culture_NNP and_CC sensitivity_NN testing_NN was_VBD carried_VBN out_IN in_IN 141_CD
        patients_NNS (_( 69_CD ._. 4_LS %_NN )_) and_CC a_DT total_NN of_IN 154_CD specimens_NNS were_VBD sent_VBN for_IN
        testing_NN ._. One_CD hundred_CD and_CC twenty_CD eight_CD patients_NNS had_VBD single_JJ
        specimen_NN sent_VBD for_IN culture_NN and_CC sensitivity_NN testing_NN ,_, 10_CD
        patients_NNS had_VBD two_CD specimens_NNS ,_, and_CC 2_CD patients_NNS ,_, three_CD
        specimens_NNS ._. Sputum_NNP was_VBD the_DT most_RBS frequent_JJ specimen_NN followed_VBN
        by_IN urine_NN and_CC blood_NN ._. The_DT results_NNS were_VBD negative_JJ in_IN 47_CD cases_NNS
        while_IN in_IN 41_CD cases_VBZ normal_JJ flora_NNS was_VBD grown_VBN ._. A_DT total_NN of_IN 163_CD
        organisms_NNS were_VBD isolated_VBN ._. The_DT predominant_NN organisms_NNS isolated_VBN
        were_VBD 
        H_NNP ._. influenzae_NN (_( n_NN =_SYM 16_CD )_) ,_, 
        E_NNP ._. coli_NNS (_( n_NN =_SYM 14_CD )_) ,_, 
        K_NNP ._. pneumoniae_NN (_( n_NN =_SYM 11_CD )_) ,_, 
        S_NNP ._. aureus_NN (_( n_NN =_SYM 9_CD )_) and_CC 
        S_NNP ._. pneumoniae_NN (_( n_NN =_SYM 9_CD )_) ._. Table_NNP 3_CD shows_VBZ
        the_DT antibiotic_JJ resistance_NN patterns_NNS of_IN the_DT commonly_RB isolated_VBN
        organisms_NNS ._. Table_NNP 4_CD shows_VBZ the_DT number_NN of_IN antibiotics_NNS to_TO which_WDT
        the_DT commonly_RB isolated_VBN organisms_NNS were_VBD resistant_JJ ._.
        The_DT most_RBS frequent_JJ organism_NN isolated_VBN in_IN the_DT sputum_NN was_VBD 
        H_NNP ._. influenzae_NN (_( n_NN =_SYM 16_CD )_) ._. These_DT
        isolates_VBZ were_VBD resistant_JJ to_TO tetracyclines_NNS in_IN 17_CD %_NN of_IN cases_NNS ,_,
        to_TO chloramphenicol_NN in_IN 18_CD ._. 2_LS %_NN of_IN cases_NNS ,_, amoxicillin_NN in_IN 20_CD %_NN of_IN
        cases_NNS ,_, cotrimoxazole_NN in_IN 66_CD %_NN of_IN cases_NNS and_CC erythromycin_NN in_IN
        71_CD ._. 4_LS %_NN of_IN cases_NNS ._. In_IN the_DT urine_NN 
        E_NNP ._. coli_NNS was_VBD the_DT most_RBS frequent_JJ
        organism_NN isolated_VBD ,_, accounting_NN for_IN 52_CD ._. 2_LS %_NN of_IN total_JJ organisms_NNS
        from_IN the_DT urine_NN ._. The_DT resistance_NN patterns_NNS of_IN 
        E_NNP ._. coli_NNS were_VBD as_IN follows_VBZ :_: gentamicin_NN
        (_( 44_CD %_NN )_) ,_, norfloxacin_NN (_( 50_CD %_NN )_) ,_, ciprofloxacin_NN (_( 55_CD %_NN )_) and_CC
        ampicillin_NN (_( 71_CD %_NN )_) ._. However_RB ,_, 25_CD %_NN of_IN 
        E_NNP ._. coli_NNS isolates_VBZ were_VBD resistant_JJ to_TO
        most_JJS antibiotics_NNS but_CC were_VBD sensitive_JJ to_TO cotrimoxazole_NN ._. The_DT
        blood_NN cultures_NNS were_VBD negative_JJ in_IN most_JJS of_IN the_DT instances_NNS ._.
      
      
        Discussion_NNP
        Antibiotic_NNP resistance_NN among_IN pathogenic_JJ microorganisms_NNS is_VBZ
        a_DT matter_NN of_IN worldwide_NN concern_NN ._. Selective_NNP pressure_NN by_IN
        antimicrobial_NN drugs_NNS is_VBZ by_IN far_RB the_DT most_RBS important_JJ driving_NN
        force_NN for_IN the_DT development_NN of_IN such_JJ resistance_NN ._. Antibiotics_NNP
        are_VBP among_IN the_DT most_RBS commonly_RB prescribed_VBN drugs_NNS in_IN hospitals_NNS
        and_CC in_IN developed_VBN countries_NNS around_IN 30_CD %_NN of_IN the_DT hospitalized_VBN
        patients_NNS are_VBP treated_VBN with_IN these_DT drugs_NNS [_NN 10_CD ]_NN ._. The_DT present_JJ
        study_NN documents_NNS that_DT 29_CD ._. 5_LS %_NN of_IN the_DT patients_NNS were_VBD prescribed_VBN
        antibiotics_NNS ._. This_DT is_VBZ very_RB similar_JJ to_TO the_DT reports_NNS from_IN
        developed_VBN countries_NNS [_NN 10_CD ]_NN ._. Antibiotic_NNP prescription_NN was_VBD
        studied_VBN over_IN 3_CD months_NNS ,_, the_DT major_JJ disadvantage_NN being_VBG that_IN
        seasonal_JJ variations_NNS in_IN antibiotic_JJ prescribing_VBG could_MD not_RB be_VB
        taken_VBN into_IN consideration_NN over_IN this_DT short_JJ period_NN ._. The_DT number_NN
        of_IN samples_NNS which_WDT were_VBD sent_VBN for_IN culture_NN and_CC sensitivity_NN
        testing_NN were_VBD small_JJ which_WDT may_MD also_RB affect_VB the_DT validity_NN of_IN
        the_DT conclusions_NNS drawn_VBN about_IN antibiotic_JJ resistance_NN ._.
        Among_IN patients_NNS admitted_VBN to_TO the_DT Internal_NNP Medicine_NNP ward_VB ,_,
        there_EX was_VBD a_DT preponderance_NN of_IN those_DT above_IN the_DT age_NN of_IN 59_CD
        years_NNS ._. This_DT factor_NN may_MD have_VB influenced_VBN antibiotic_JJ
        prescribing_VBG as_IN older_JJR patients_NNS are_VBP more_RBR likely_JJ to_TO be_VB sick_JJ
        and_CC to_TO have_VB more_RBR serious_JJ illnesses_NNS ._. Also_RB paediatric_JJ
        patients_NNS (_( <_NN 12_CD years_NNS )_) were_VBD not_RB included_VBN in_IN the_DT analysis_NN
        as_IN they_PRP are_VBP admitted_VBN to_TO the_DT Paediatric_NNP Medicine_NNP ward_VB ._.
        Brahmins_NNP and_CC Gurungs_NNP were_VBD the_DT 2_CD major_JJ ethnic_JJ groups_NNS
        encountered_VBD in_IN our_PRP$ study_NN ._. The_DT data_NNS on_IN the_DT ethnic_JJ
        composition_NN of_IN patients_NNS gives_VBZ information_NN on_IN the_DT
        utilization_NN of_IN the_DT hospital_NN by_IN the_DT different_JJ ethnic_JJ groups_NNS
        in_IN Kaski_NNP and_CC the_DT neighbouring_VBG districts_NNS ._. A_DT substantial_JJ
        number_NN of_IN Gurungs_NNP are_VBP ex-servicemen_JJ and_CC our_PRP$ hospital_NN has_VBZ
        tied_VBN up_RP with_IN the_DT Gorkha_NNP Welfare_NNP Society_NNP of_IN the_DT British_NNP
        Gorkhas_NNP ._. A_DT Gorkha_NNP Welfare_NNP Scheme_NNP (_( GWS_NNP )_) has_VBZ been_VBN introduced_VBN
        for_IN these_DT ex-servicemen_JJ and_CC their_PRP$ dependents_NNS ._. Seven_CD of_IN the_DT
        56_CD Gurungs_NNP were_VBD benefited_VBN by_IN GWS_NNP ._.
        Sixty-eight_NNP patients_NNS (_( 33_CD ._. 5_LS %_NN )_) belonged_VBD to_TO low_JJ
        socioeconomic_JJ groups_NNS ._. The_DT Manipal_NNP Teaching_NNP Hospital_NNP is_VBZ a_DT
        private_JJ sector_NN health_NN care_NN provider_NN where_WRB most_JJS of_IN the_DT
        patients_NNS have_VBP to_TO pay_VB for_IN their_PRP$ treatment_NN and_CC medicines_NNS ._. We_PRP
        have_VBP created_VBN a_DT Poor_NNP Patients_NNPS Fund_NNP (_( PPF_NNP )_) in_IN our_PRP$ hospital_NN to_TO
        help_VB the_DT economically_RB deprived_VBN patients_NNS ._. Partial_NNP or_CC
        sometimes_RB even_RB full_JJ concession_NN in_IN hospital_NN charges_NNS may_MD be_VB
        offered_VBN to_TO these_DT patients_NNS ._. Thirty-eight_NNP of_IN the_DT 203_CD patients_NNS
        (_( 18_CD ._. 7_CD %_NN )_) benefited_VBD from_IN the_DT PPF_NNP at_IN our_PRP$ hospital_NN ,_, 32_CD of_IN these_DT
        patients_NNS belonged_VBD to_TO a_DT low_JJ socioeconomic_JJ group_NN ._.
        The_DT median_JJ duration_NN of_IN hospitalization_NN was_VBD 5_CD days_NNS and_CC
        the_DT interquartile_NN range_NN was_VBD 3_CD days_NNS ._. The_DT majority_NN of_IN
        patients_NNS were_VBD hospitalized_VBN for_IN a_DT time_NN period_NN between_IN 4_CD to_TO 7_CD
        days_NNS ._. In_IN a_DT previous_JJ study_NN [_NN 11_CD ]_NN in_IN the_DT Intensive_NNP Care_NNP Unit_NNP
        (_( ICU_NNP )_) of_IN our_PRP$ hospital_NN ,_, the_DT mean_JJ Â±_NN SD_NNP period_NN of_IN
        hospitalization_NN was_VBD 3_CD ._. 84_CD Â±_NN 3_CD ._. 14_CD days_NNS and_CC economic_JJ
        constraints_NNS were_VBD a_DT major_JJ reason_NN for_IN seeking_VBG an_DT early_JJ
        discharge_NN from_IN the_DT ICU_NNP ._. In_IN this_DT study_NN median_JJ duration_NN of_IN
        hospitalization_NN for_IN patients_NNS receiving_VBG systemic_JJ antibiotics_NNS
        was_VBD significantly_RB higher_JJR compared_VBN to_TO patients_NNS not_RB receiving_VBG
        antibiotics_NNS ._. This_DT is_VBZ similar_JJ to_TO the_DT results_NNS observed_VBD in_IN a_DT
        Hungarian_JJ study_NN [_NN 12_CD ]_NN ._.
        COPD_NNP ,_, LRTI_NNP and_CC UTI_NNP were_VBD the_DT most_RBS frequent_JJ clinical_JJ
        conditions_NNS for_IN which_WDT an_DT antibiotic_NN was_VBD prescribed_VBN ._. The_DT
        morbidity_NN profile_NN of_IN antibiotic_JJ use_NN broadly_RB corresponds_NNS to_TO
        that_DT observed_VBD in_IN an_DT Indian_JJ study_NN [_NN 13_CD ]_NN ._. In_IN another_DT study_NN
        from_IN Israel_NNP [_NN 14_CD ]_NN ,_, antibiotics_NNS were_VBD most_RBS commonly_RB used_VBN in_IN
        respiratory_JJ tract_NN infection_NN and_CC UTI_NNP followed_VBN by_IN sepsis_NN and_CC
        intra-abdominal_JJ infections_NNS ._. However_RB ,_, the_DT authors_NNS had_VBD looked_VBN
        at_IN the_DT entire_JJ hospital_NN patient_NN population_NN [_NN 14_CD ]_NN ._.
        Sixty-seven_NNP percent_NN of_IN antibiotics_NNS were_VBD prescribed_VBN from_IN
        the_DT Essential_NNP drug_NN list_NN of_IN Nepal_NNP [_NN 8_CD ]_NN and_CC 65_CD ._. 1_LS %_NN were_VBD
        prescribed_VBN from_IN the_DT WHO_WP Essential_NNP drug_NN list_NN [_NN 9_CD ]_NN ._. The_DT
        Manipal_NNP Teaching_NNP Hospital_NNP is_VBZ a_DT tertiary_JJ care_NN provider_NN in_IN
        the_DT Pokhara_NNP valley_NN and_CC due_JJ to_TO various_JJ reasons_NNS it_PRP is_VBZ
        sometimes_RB necessary_JJ to_TO use_VB antibiotics_NNS which_WDT may_MD not_RB be_VB
        covered_VBN in_IN the_DT Essential_NNP drug_NN lists_NNS ._. The_DT Essential_NNP drug_NN
        lists_NNS are_VBP mainly_RB for_IN primary_JJ health_NN care_NN and_CC their_PRP$ utility_NN
        in_IN our_PRP$ study_NN is_VBZ more_RBR limited_JJ ._.
        The_DT average_JJ number_NN of_IN drugs_NNS per_IN prescription_NN is_VBZ an_DT
        important_JJ index_NN of_IN a_DT prescription_NN audit_NN ._. It_PRP is_VBZ preferable_JJ
        to_TO keep_VB the_DT number_NN of_IN drugs_NNS per_IN prescription_NN as_RB low_JJ as_IN
        possible_JJ to_TO minimize_VB the_DT risk_NN of_IN drug_NN interactions_NNS ,_,
        development_NN of_IN bacterial_JJ resistance_NN and_CC hospital_NN costs_NNS [_NN 15_CD
        ]_NN ._. We_PRP did_VBD not_RB look_VB at_IN the_DT co-prescribed_JJ drugs_NNS here_RB ,_, but_CC
        concentrated_VBD only_RB on_IN antibiotics_NNS ._. The_DT average_JJ number_NN of_IN
        antibiotics_NNS prescribed_VBN during_IN the_DT hospital_NN stay_NN was_VBD 1_CD ._. 7_CD ,_,
        which_WDT is_VBZ similar_JJ to_TO the_DT observation_NN in_IN an_DT Indian_JJ study_NN [_NN 5_CD
        ]_NN ._. The_DT antibiotics_NNS most_RBS frequently_RB prescribed_VBN together_RB
        were_VBD ampicillin_NN and_CC gentamicin_NN ._. Three_CD or_CC more_JJR antibiotics_NNS
        were_VBD prescribed_VBN to_TO patients_NNS in_IN whom_WP the_DT antibiotics_NNS were_VBD
        changed_VBN either_CC after_IN reviewing_VBG the_DT culture_NN and_CC sensitivity_NN
        results_NNS or_CC due_JJ to_TO lack_NN of_IN improvement_NN in_IN the_DT clinical_JJ
        condition_NN ._. Three_CD or_CC more_JJR antibiotics_NNS were_VBD started_VBN together_RB
        in_IN seriously_RB ill_JJ patients_NNS ._.
        Mean_VB Â±_NN SD_NNP cost_NN of_IN antibiotics_NNS prescribed_VBN during_IN the_DT
        hospital_NN stay_NN was_VBD 16_CD ._. 5_LS Â±_NN 13_CD ._. 4_LS US_NNP $_$ ._. The_DT medicines_NNS were_VBD
        purchased_VBN by_IN the_DT patients_NNS from_IN the_DT hospital_NN pharmacy_NN ,_, the_DT
        cost_NN price_NN of_IN drugs_NNS in_IN the_DT hospital_NN pharmacy_NN being_VBG less_JJR
        than_IN the_DT open_JJ market_NN price_NN ,_, (_( the_DT pharmacy_NN buying_VBG medicines_NNS
        in_IN bulk_NN and_CC passing_VBG the_DT discount_NN on_IN to_TO patients_NNS )_) ._. The_DT
        difference_NN in_IN cost_NN varied_VBD from_IN 2_CD to_TO 4_CD %_NN for_IN different_JJ drugs_NNS ._.
        The_DT total_JJ cost_NN incurred_VBN by_IN the_DT patients_NNS during_IN the_DT period_NN
        of_IN hospital_NN stay_NN was_VBD 33_CD ._. 4_LS Â±_NN 16_CD ._. 2_LS US_NNP $_$ ._. The_DT cost_NN incurred_VBN on_IN
        hospital_NN and_CC nursing_NN charges_NNS ,_, other_JJ co-prescribed_JJ drugs_NNS and_CC
        laboratory_NN and_CC other_JJ investigations_NNS were_VBD included_VBN in_IN the_DT
        total_JJ cost_NN ._.
        Fifty-one_NNP percent_NN of_IN the_DT patients_NNS were_VBD prescribed_VBN
        antibiotics_NNS by_IN the_DT parenteral_NN route_NN ._. In_IN a_DT study_NN reported_VBD
        from_IN South_JJ India_NNP [_NN 2_CD ]_NN ,_, 36_CD %_NN of_IN antibiotics_NNS were_VBD prescribed_VBN
        by_IN the_DT parenteral_NN route_NN ._. In_IN the_DT Israeli_JJ study_NN [_NN 14_CD ]_NN ,_, 64_CD %_NN
        of_IN antibiotics_NNS were_VBD prescribed_VBN parenterally_RB ._. Parenteral_NNP
        antibiotics_NNS in_IN the_DT study_NN were_VBD prescribed_VBN for_IN a_DT median_JJ
        duration_NN of_IN 5_CD days_NNS and_CC the_DT interquartile_NN range_NN was_VBD 3_CD days_NNS ._.
        The_DT duration_NN of_IN use_NN of_IN parenteral_NN antibiotics_NNS may_MD be_VB
        decreased_VBN and_CC the_DT patients_NNS switched_VBD over_IN earlier_RBR to_TO oral_JJ
        antibiotics_NNS ._.
        In_IN Canada_NNP a_DT route_NN conversion_NN program_NN on_IN the_DT prescribing_VBG
        of_IN antimicrobials_NNS succeeded_VBN in_IN reducing_VBG the_DT frequency_NN of_IN
        use_NN of_IN parenteral_NN antibiotics_NNS [_NN 16_CD ]_NN ._. Parenteral_NNP
        antibiotics_NNS are_VBP costly_JJ and_CC the_DT cost_NN of_IN drugs_NNS is_VBZ a_DT major_JJ
        factor_NN influencing_VBG treatment_NN in_IN a_DT poor_JJ country_NN like_IN Nepal_NNP ._.
        In_IN our_PRP$ hospital_NN ,_, patients_NNS are_VBP usually_RB discharged_VBN once_RB the_DT
        antibiotics_NNS are_VBP changed_VBN from_IN the_DT parenteral_NN to_TO the_DT oral_JJ
        route_NN ._. One_CD hundred_CD and_CC eighteen_NN patients_NNS were_VBD from_IN urban_JJ
        areas_NNS and_CC their_PRP$ houses_NNS were_VBD accessible_JJ by_IN all_DT weather_NN
        roads_NNS ,_, these_DT patients_NNS can_MD either_CC return_VB to_TO the_DT hospital_NN or_CC
        visit_VB a_DT neighbouring_VBG health_NN care_NN facility_NN in_IN case_NN of_IN
        problems_NNS after_IN being_VBG discharged_VBN ._. Early_RB switchover_NN to_TO oral_JJ
        antibiotics_NNS may_MD be_VB more_RBR difficult_JJ for_IN rural_JJ patients_NNS as_IN
        they_PRP may_MD have_VB difficulty_NN in_IN accessing_VBG medical_JJ care_NN in_IN case_NN
        of_IN problems_NNS ._. The_DT patients_NNS are_VBP generally_RB unwilling_JJ to_TO stay_VB
        in_IN the_DT hospital_NN after_IN injectable_JJ drugs_NNS have_VBP been_VBN stopped_VBN ._.
        Economic_JJ considerations_NNS may_MD be_VB partly_RB responsible_JJ for_IN the_DT
        desire_NN to_TO continue_VB further_JJ treatment_NN at_IN home_NN ._. The_DT patients_NNS
        can_MD be_VB educated_VBN about_IN the_DT need_NN for_IN remaining_VBG under_IN
        observation_NN in_IN the_DT hospital_NN even_RB after_IN the_DT stoppage_NN of_IN
        parenteral_NN drugs_NNS ,_, thus_RB a_DT programme_NN similar_JJ to_TO the_DT one_CD in_IN
        the_DT Canadian_JJ study_NN could_MD be_VB implemented_VBN in_IN our_PRP$ hospital_NN for_IN
        cost-effective_JJ use_NN of_IN parenteral_NN antibiotics_NNS ._.
        Antibiotics_NNP were_VBD used_VBN for_IN BPI_NNP in_IN 65_CD patients_NNS ._. One_CD
        hundred_CD and_CC twelve_CD patient_NN antibiotics_NNS were_VBD prescribed_VBN ._. The_DT
        antibiotics_NNS were_VBD started_VBN in_IN BPI_NNP after_IN sending_VBG specimens_NNS for_IN
        culture_NN and_CC sensitivity_NN testing_NN ._. In_IN 42_CD patients_NNS the_DT
        empirical_JJ use_NN of_IN the_DT antibiotic_JJ conformed_JJ to_TO the_DT culture_NN
        and_CC sensitivity_NN patterns_NNS of_IN organisms_NNS isolated_VBN and_CC hence_RB
        the_DT antibiotic_NN was_VBD continued_VBN ._. In_IN 15_CD patients_NNS the_DT antibiotic_NN
        was_VBD changed_VBN after_IN reviewing_VBG the_DT sensitivity_NN report_NN ._. In_IN 8_CD
        patients_NNS though_IN the_DT organism_NN was_VBD resistant_JJ to_TO the_DT
        antibiotic_NN ,_, the_DT patient_NN improved_VBN clinically_RB and_CC the_DT use_NN of_IN
        the_DT antibiotic_NN was_VBD continued_VBN ._. Delay_NNP in_IN receiving_VBG the_DT
        sensitivity_NN reports_NNS was_VBD a_DT problem_NN encountered_VBD and_CC may_MD have_VB
        delayed_VBN switching_VBG over_IN the_DT patient_NN to_TO the_DT sensitive_JJ
        antibiotic_NN ._. Steps_VBZ which_WDT could_MD be_VB taken_VBN to_TO quicken_VB the_DT
        report_NN availability_NN are_VBP :_:
        a_DT )_) immediate_JJ transport_NN and_CC processing_NN of_IN the_DT specimen_NN
        after_IN collection_NN
        b_SYM )_) constant_JJ monitoring_NN of_IN the_DT culture_NN systems_NNS to_TO detect_VB
        growth_NN
        c_SYM )_) identification_NN of_IN the_DT organism_NN and_CC antibiotic_JJ
        sensitivity_NN testing_NN (_( AST_NNP )_) to_TO be_VB done_VBN at_IN 16_CD h_NN
        d_SYM )_) reading_NN of_IN the_DT AST_NNP to_TO be_VB taken_VBN 16_CD h_NN after_IN putting_VBG the_DT
        antibiotic_JJ disc_NN
        e_SYM )_) immediate_JJ dispatch_NN ,_, collection_NN and_CC interpretation_NN of_IN
        the_DT results_NNS ._.
        In_IN our_PRP$ hospital_NN due_JJ to_TO logistical_JJ problems_NNS these_DT steps_NNS
        cannot_NN be_VB followed_VBN strictly_RB within_IN the_DT specified_VBN time_NN
        period_NN ,_, hence_RB the_DT results_NNS are_VBP delayed_VBN by_IN about_IN 12_CD to_TO 24_CD
        h_NN ._.
        In_IN case_NN of_IN blood_NN culture_NN ,_, the_DT biphasic_JJ culture_NN system_NN is_VBZ
        used_VBN in_IN which_WDT growth_NN is_VBZ observed_VBN ,_, either_CC by_IN detection_NN of_IN
        turbidity_NN in_IN the_DT liquid_JJ media_NNS or_CC by_IN growth_NN in_IN the_DT solid_JJ
        media_NNS ._. However_RB ,_, a_DT continuous_JJ automated_VBN monitoring_VBG system_NN
        such_JJ as_IN BACTALERT_NNP could_MD save_VB a_DT substantial_JJ amount_NN of_IN time_NN ._.
        This_DT system_NN is_VBZ not_RB being_VBG used_VBN at_IN present_JJ as_IN the_DT sample_NN load_NN
        is_VBZ less_JJR and_CC hence_RB it_PRP is_VBZ not_RB cost_VB effective_JJ ._.
        Antibiotics_NNP were_VBD used_VBN in_IN non-_NN BPI_NNP in_IN 62_CD %_NN of_IN the_DT cases_NNS ._. In_IN
        our_PRP$ previous_JJ study_NN in_IN ICU_NNP patients_NNS [_NN 11_CD ]_NN 84_CD ._. 5_LS %_NN of_IN the_DT
        antibiotics_NNS were_VBD prescribed_VBN without_IN bacteriological_JJ
        support_NN ._. In_IN an_DT Indian_JJ study_NN [_NN 2_CD ]_NN 62_CD %_NN of_IN prescriptions_NNS were_VBD
        therapeutic_JJ ,_, of_IN which_WDT 36_CD %_NN were_VBD therapeutic_JJ prescriptions_NNS
        without_IN bacteriological_JJ support_NN while_IN 59_CD %_NN were_VBD on_IN a_DT
        bacteriological_JJ basis_NN ._.
        Ampicillin_NNP ,_, amoxicillin_NN ,_, metronidazole_NN ,_, ciprofloxacin_NN
        and_CC crystalline_JJ penicillin_NN were_VBD the_DT 5_CD most_RBS commonly_RB
        prescribed_VBN antibiotics_NNS ._. In_IN many_JJ patients_NNS treatment_NN was_VBD
        started_VBN with_IN parenteral_NN ampicillin_NN which_WDT later_RB changed_VBN to_TO
        oral_JJ amoxicillin_NN once_RB the_DT condition_NN of_IN the_DT patient_NN
        improved_VBN ._. The_DT DDD_NNP /_NN 100_CD bed-days_JJ of_IN ampicillin_NN was_VBD 27_CD ._. 5_LS while_IN
        that_DT of_IN amoxicillin_NN was_VBD 17_CD ._. 5_LS ._. These_DT figures_NNS are_VBP higher_JJR than_IN
        those_DT reported_VBN by_IN Mikic_NNP et_CC al_NN [_NN 17_CD ]_NN ._. In_IN their_PRP$ study_NN the_DT
        DDD_NNP /_NN 100_CD bed-days_JJ of_IN aminopenicillins_NNS was_VBD 5_CD ._. 1_CD ;_: ampicillin_NN
        was_VBD used_VBN in_IN 37_CD ._. 6_CD %_NN of_IN patients_NNS and_CC amoxicillin_NN in_IN 13_CD ._. 1_LS %_NN ._. The_DT
        antibiotic_JJ use_NN in_IN our_PRP$ study_NN was_VBD 108_CD ._. 5_LS DDDs_NNP /_NN 100_CD bed-days_JJ ._. We_PRP
        have_VBP no_DT data_NNS on_IN the_DT long_JJ trends_NNS of_IN antibiotic_JJ utilization_NN
        in_IN our_PRP$ hospital_NN ._. Castro_NNP et_CC al_NN [_NN 18_CD ]_NN reported_VBD that_IN the_DT use_NN
        of_IN antibiotics_NNS in_IN a_DT Brazilian_JJ hospital_NN had_VBD increased_VBN from_IN
        83_CD ._. 8_CD DDDs_NNP /_NN 100_CD bed-days_JJ in_IN 1990_CD to_TO 124_CD ._. 6_CD DDDs_NNP /_NN 100_CD bed-days_JJ
        in_IN 1996_CD ._. The_DT introduction_NN of_IN a_DT hospital_NN antibiotic_JJ policy_NN
        helped_VBD to_TO reduce_VB antibiotic_JJ utilization_NN at_IN a_DT university_NN
        hospital_NN from_IN 45_CD ._. 9_CD DDDs_NNP /_NN 100_CD bed-days_JJ to_TO 32_CD ._. 9_CD DDDs_NNP /_NN 100_CD
        bed-days_JJ [_NN 19_CD ]_NN ._.
        The_DT use_NN of_IN cephalosporins_NNS in_IN our_PRP$ study_NN was_VBD less_JJR than_IN
        that_DT reported_VBD in_IN the_DT literature_NN [_NN 20_CD 21_CD ]_NN ._. However_RB ,_, direct_JJ
        comparisons_NNS of_IN cephalosporin_NN utilization_NN may_MD not_RB be_VB
        appropriate_JJ as_IN one_CD of_IN the_DT studies_NNS [_NN 20_CD ]_NN was_VBD carried_VBN out_RP
        both_DT inside_IN and_CC outside_IN of_IN health_NN care_NN facilities_NNS in_IN Norway_NNP
        while_IN the_DT other_JJ study_NN [_NN 21_CD ]_NN was_VBD carried_VBN in_IN a_DT rural_JJ
        hospital_NN ._. In_IN the_DT Norwegian_JJ study_NN ,_, cephalosporins_NNS
        represented_VBD 16_CD %_NN of_IN the_DT use_NN of_IN antibacterials_NNS in_IN hospitals_NNS ,_,
        while_IN in_IN the_DT study_NN carried_VBD out_RB at_IN a_DT rural_JJ hospital_NN ,_,
        ceftriaxone_NN and_CC cefuroxime_NN together_RB accounted_VBD for_IN 30_CD ._. 8_CD %_NN of_IN
        the_DT total_JJ antibiotic_JJ days_NNS ._. Antibiotic_NNP utilization_NN in_IN
        different_JJ specialties_NNS may_MD have_VB been_VBN considered_VBN in_IN the_DT above_JJ
        studies_NNS [_NN 20_CD 21_CD ]_NN while_IN our_PRP$ study_NN was_VBD confined_VBN to_TO the_DT
        Internal_NNP Medicine_NNP ward_VB ._. The_DT isolated_VBN organisms_NNS are_VBP becoming_VBG
        resistant_JJ to_TO the_DT commonly_RB used_VBN antibiotics_NNS and_CC
        cephalosporins_NNS may_MD have_VB to_TO be_VB prescribed_VBN in_IN resistant_JJ
        cases_NNS ._. Cephalosporins_NNP are_VBP available_JJ in_IN the_DT hospital_NN
        pharmacy_NN but_CC more_JJR data_NNS on_IN sensitivity_NN patterns_NNS is_VBZ required_VBN
        before_IN they_PRP can_MD be_VB more_RBR frequently_RB prescribed_VBN ._.
        A_DT total_NN of_IN 163_CD organisms_NNS were_VBD isolated_VBN from_IN the_DT
        specimens_NNS sent_VBD for_IN culture_NN and_CC sensitivity_NN testing_NN ._. The_DT
        small_JJ number_NN of_IN specimens_NNS may_MD ,_, however_RB ,_, limit_NN conclusions_NNS
        about_IN antibiotic_JJ resistance_NN ._. Carrying_VBG out_RP the_DT study_NN for_IN a_DT
        longer_JJR period_NN of_IN time_NN could_MD partly_RB overcome_VB this_DT lacuna_NN ._. 
        H_NNP ._. influenzae_NN ,_, E_NNP ._. coli_NNS ,_, K_NNP ._. pneumoniae_NN ,_, S_NNP ._.
        aureus_NN and_CC 
        S_NNP ._. pneumoniae_NN were_VBD the_DT commonest_NN
        organisms_NNS isolated_VBN and_CC were_VBD resistant_JJ to_TO cotrimoxazole_NN ,_,
        chloramphenicol_NN and_CC co-amoxiclav_JJ in_IN a_DT significant_JJ number_NN of_IN
        cases_NNS ._. This_DT maybe_RB ,_, is_VBZ one_CD of_IN the_DT reasons_NNS for_IN the_DT decreased_VBN
        use_NN of_IN sulfonamides_NNS in_IN the_DT Internal_NNP Medicine_NNP ward_VB ._. Urine_NNP
        was_VBD the_DT second_JJ most_RBS common_JJ specimen_NN sent_VBD for_IN culture_NN and_CC
        sensitivity_NN testing_NN ._. In_IN a_DT study_NN reported_VBD from_IN Trinidad_NNP [_NN 22_CD
        ]_NN ,_, 
        E_NNP ._. coli_NNS was_VBD the_DT most_RBS frequent_JJ isolate_VB
        from_IN urine_NN samples_NNS and_CC was_VBD mostly_RB resistant_JJ to_TO
        tetracycline_NN ,_, trimethoprim_NN and_CC cotrimoxazole_NN ._. The_DT low_JJ
        number_NN of_IN samples_NNS in_IN our_PRP$ study_NN makes_VBZ it_PRP difficult_JJ to_TO draw_VB
        firm_NN conclusions_NNS but_CC an_DT increasing_VBG resistance_NN of_IN 
        E_NNP ._. coli_NNS and_CC 
        S_NNP ._. aureus_NN to_TO commonly_RB used_VBN
        antibiotics_NNS is_VBZ observed_VBN ._.
        Antibiotic_NNP resistance_NN is_VBZ an_DT increasingly_RB encountered_VBN
        problem_NN in_IN the_DT Internal_NNP Medicine_NNP ward_NN of_IN our_PRP$ hospital_NN ._. We_PRP
        are_VBP in_IN the_DT process_NN of_IN formulating_VBG an_DT antibiotic_JJ use_NN policy_NN
        and_CC at_IN present_JJ ,_, only_RB have_VBP antibiotic_JJ use_NN guidelines_NNS for_IN the_DT
        department_NN of_IN Internal_NNP Medicine_NNP ._. We_PRP are_VBP working_VBG to_TO develop_VB
        a_DT system_NN to_TO recognize_VB and_CC report_VB trends_NNS in_IN antibiotic_JJ
        resistance_NN within_IN our_PRP$ institution_NN ._. However_RB ,_, a_DT system_NN to_TO
        rapidly_RB detect_VB and_CC report_VB resistant_JJ organisms_NNS in_IN individual_JJ
        patients_NNS should_MD be_VB in_IN place_NN to_TO ensure_VB a_DT rapid_JJ response_NN by_IN
        caregivers_NNS ._. Prevention_NNP and_CC control_NN of_IN the_DT spread_NN of_IN
        antibiotic-resistant_JJ organisms_NNS will_MD require_VB increased_VBN
        adherence_NN to_TO basic_JJ infection_NN control_NN policies_NNS and_CC
        procedures_NNS ,_, incorporation_NN of_IN antimicrobial_NN resistance_NN
        strategies_NNS into_IN institutional_JJ goals_NNS and_CC development_NN of_IN a_DT
        plan_NN to_TO deal_VB with_IN patients_NNS colonized_JJ with_IN resistant_JJ
        organisms_NNS [_NN 23_CD ]_NN ._.
        In_IN a_DT recent_JJ study_NN [_NN 24_CD ]_NN ,_, a_DT vast_JJ majority_NN of_IN physicians_NNS
        (_( 97_CD %_NN )_) believed_VBN that_IN widespread_JJ and_CC inappropriate_JJ use_NN of_IN
        antimicrobials_NNS was_VBD an_DT important_JJ cause_NN of_IN resistance_NN ._.
        However_RB ,_, only_RB 60_CD %_NN favoured_JJ restricting_VBG the_DT use_NN of_IN
        broad-spectrum_JJ antibiotics_NNS [_NN 25_CD ]_NN ._. Also_RB it_PRP has_VBZ been_VBN found_VBN
        that_IN the_DT public_JJ health_NN concern_NN of_IN contributing_VBG to_TO the_DT
        problem_NN of_IN antibiotic_JJ resistance_NN does_VBZ not_RB exert_VB a_DT strong_JJ
        impact_NN on_IN physician_NN prescribing_VBG decisions_NNS for_IN community_NN
        acquired_VBD pneumonia_NN ._. All_DT these_DT factors_NNS may_MD have_VB to_TO be_VB taken_VBN
        into_IN consideration_NN while_IN developing_VBG a_DT programme_NN to_TO reduce_VB
        the_DT use_NN of_IN antibiotics_NNS ._.
      
      
        Conclusions_NNP
        The_DT high_JJ rate_NN of_IN prescription_NN of_IN parenteral_NN antibiotics_NNS
        is_VBZ a_DT matter_NN of_IN concern_NN ._. Decreasing_NNP the_DT prescribing_VBG of_IN
        parenteral_NN antibiotics_NNS and_CC an_DT early_JJ switch_NN to_TO oral_JJ
        antibiotics_NNS will_MD significantly_RB reduce_VB the_DT expenditure_NN
        incurred_VBN ._. An_DT intravenous_JJ to_TO oral_JJ antibiotic_JJ conversion_NN
        program_NN can_MD be_VB instituted_VBN ._. Quickening_NNP the_DT availability_NN of_IN
        culture_NN and_CC sensitivity_NN reports_NNS will_MD enable_VB the_DT treatment_NN
        to_TO have_VB a_DT sound_NN bacteriological_JJ basis_NN ._. Antibiotic_NNP
        resistance_NN is_VBZ becoming_VBG a_DT problem_NN and_CC formulation_NN of_IN a_DT
        hospital_NN antibiotic_JJ use_NN policy_NN is_VBZ a_DT matter_NN of_IN urgent_JJ
        concern_NN ._. An_DT educational_JJ programme_NN and_CC an_DT antibiotic_JJ order_NN
        form_NN may_MD be_VB useful_JJ initiatives_NNS to_TO reduce_VB antibiotic_JJ use_NN ._.
        Guidelines_NNS for_IN antibiotic_JJ use_NN in_IN the_DT community_NN and_CC
        restricting_VBG the_DT level_NN of_IN health_NN care_NN practitioners_NNS who_WP can_MD
        prescribe_VB antibiotics_NNS are_VBP required_VBN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Author_NN 's_POS contributions_NNS
        PRS_NNP planned_VBD the_DT study_NN ,_, collected_VBD the_DT data_NNS ,_, analyzed_VBD the_DT
        data_NNS ,_, compiled_VBN the_DT results_NNS and_CC wrote_VBD the_DT manuscript_NN ._. PP_NNP
        helped_VBD in_IN planning_VBG the_DT study_NN ,_, collecting_VBG the_DT data_NNS and_CC
        writing_VBG the_DT manuscript_NN ._. NS_NNP helped_VBD in_IN planning_VBG the_DT study_NN and_CC
        analyzing_VBG the_DT data_NNS and_CC working_VBG out_RP the_DT cost_NN of_IN antibiotic_JJ
        therapy_NN ._. JME_NNP helped_VBD in_IN collecting_VBG the_DT data_NNS ,_, analyzing_VBG the_DT
        culture_NN and_CC sensitivity_NN results_NNS and_CC writing_VBG the_DT manuscript_NN ._.
        KNB_NNP helped_VBD in_IN overall_JJ planning_NN of_IN the_DT study_NN ,_, analyzing_VBG the_DT
        culture_NN and_CC sensitivity_NN data_NNS and_CC writing_VBG the_DT
        manuscript_NN ._.
      
    
  
